270 related articles for article (PubMed ID: 27422150)
1. The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.
Lv X; Si T; Wang G; Wang H; Liu Q; Hu C; Wang J; Su Y; Huang Y; Jiang H; Yu X
BMC Psychiatry; 2016 Jul; 16():240. PubMed ID: 27422150
[TBL] [Abstract][Full Text] [Related]
2. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
Trials; 2011 Jan; 12():4. PubMed ID: 21208417
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
4. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
[TBL] [Abstract][Full Text] [Related]
5. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
Trials; 2013 Jul; 14():224. PubMed ID: 23866851
[TBL] [Abstract][Full Text] [Related]
6. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder.
Tadić A; Wagner S; Gorbulev S; Dahmen N; Hiemke C; Braus DF; Lieb K
BMC Psychiatry; 2011 Jan; 11():16. PubMed ID: 21269443
[TBL] [Abstract][Full Text] [Related]
8. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
Freeman MP; Fava M; Dirks B; Jha MK; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
Depress Anxiety; 2020 May; 37(5):485-495. PubMed ID: 32301591
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
[TBL] [Abstract][Full Text] [Related]
10. EEG microstates as markers of major depressive disorder and predictors of response to SSRIs therapy.
Lei L; Liu Z; Zhang Y; Guo M; Liu P; Hu X; Yang C; Zhang A; Sun N; Wang Y; Zhang K
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jun; 116():110514. PubMed ID: 35085607
[TBL] [Abstract][Full Text] [Related]
11. [Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: results of the ORACLE survey].
Spadone C; Sylvestre M; Chiarelli P; Richard-Berthe C
Encephale; 2005; 31(6 Pt 1):698-704. PubMed ID: 16462689
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine in major depressive disorder -- opportunities and pitfalls.
Miller DB; O'Callaghan JP
Metabolism; 2013 Jan; 62 Suppl 1(0 1):S34-9. PubMed ID: 23021040
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
14. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
Knorr UB
Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
[TBL] [Abstract][Full Text] [Related]
15. A patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial.
Vigod S; Hussain-Shamsy N; Grigoriadis S; Howard LM; Metcalfe K; Oberlander TF; Schram C; Stewart DE; Taylor VH; Dennis CL
Trials; 2016 Feb; 17(1):110. PubMed ID: 26923796
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial.
Siqueira CC; Valiengo LL; Carvalho AF; Santos-Silva PR; Missio G; de Sousa RT; Di Natale G; Gattaz WF; Moreno RA; Machado-Vieira R
PLoS One; 2016; 11(5):e0154195. PubMed ID: 27152523
[TBL] [Abstract][Full Text] [Related]
17. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
[TBL] [Abstract][Full Text] [Related]
18. A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study.
Zhou R; Zhang H; He S; Li Y; Xu G; Huang J; Wang H; Wang Q; Li B; Wang X; Chen N; Li F; Li X; Liu M; Peng D
Trials; 2023 May; 24(1):308. PubMed ID: 37143128
[TBL] [Abstract][Full Text] [Related]
19. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
[TBL] [Abstract][Full Text] [Related]
20. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
